Diagnostic Performance and Safety of Ragweed Pollen and Dog Dander Skin Prick Test Solutions
A Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Diagnostic Performance and Safety of Ragweed Pollen and Dog Dander Skin Prick Test Solutions in Chinese Participants Undergoing Allergy Testing
This multicenter, open-label, Phase III interventional study will evaluate the diagnostic performance and safety of ragweed pollen and dog dander skin prick test (SPT) solutions in adults in China with current or previous allergic diseases. Participants will undergo serum allergen-specific immunoglobulin E (sIgE) testing using the Thermo Fisher Scientific ImmunoCAP system. Each enrolled participant will receive one skin prick with ragweed pollen solution (3,500 DU/mL), dog dander solution (19,500 DU/mL), dog dander solution (39,000 DU/mL), and positive and negative controls. Wheal responses will be assessed 15-20 minutes after skin pricking. Diagnostic sensitivity and specificity will be determined separately for each test solution against the corresponding serum sIgE classification (cutoff ≥0.70 kUA/L). Safety will be assessed through adverse events, symptoms, vital signs, physical examinations, and laboratory tests.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Wang Jiazheng
- Numéro de téléphone: +8615800536923
- E-mail: wangjiazheng@wolwobiotech.com
Lieux d'étude
-
-
-
Beijing, Chine, 100730
- Beijing Tongren Hospital, Capital Medical University
-
Contact:
- Zhang Luo
- Numéro de téléphone: +861065141136
- E-mail: dr.luozhang@139.com
-
-
Hubei
-
Wuhan, Hubei, Chine, 430030
- Tongji Hospital, Tongji Medical College of Hust
-
Contact:
- Zhu Rongfei
- Numéro de téléphone: +862783662912
- E-mail: Zrf13092@163.com
-
-
Shanxi
-
Taiyuan, Shanxi, Chine, 030032
- Shanxi Bethune Hospital
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male or female participants aged 18-60 years, inclusive.
- Participants with a current or previous history of allergic diseases, such as allergic rhinitis, allergic conjunctivitis, or allergic asthma.
- Participants who are able to understand the study and voluntarily provide written informed consent.
Exclusion Criteria:
- History of needle-related syncope or vasovagal reactions to the sight of blood.
- Pregnant or breastfeeding women.
- History of malignant tumors.
- Currently receiving beta-blockers or angiotensin-converting enzyme inhibitors and unable to discontinue treatment during the study.
- Currently experiencing a severe allergic reaction or having a history of severe allergic reactions, including generalized urticaria, severe or more serious acute asthma exacerbations, or anaphylactic shock.
- Use of topical corticosteroids or topical calcineurin inhibitors at the intended skin prick site within 7 days before SPT.
- Systemic use of antihistamines or antihistamine-containing combination medications before SPT, with a discontinuation period not exceeding five elimination half-lives of the antihistamine.
- Use of short-acting systemic corticosteroids within 2 days, intermediate-acting systemic corticosteroids within 5 days, or long-acting systemic corticosteroids within 12 days before SPT.
- Systemic use of immunosuppressants within 14 days before SPT.
- Use of phenothiazine antipsychotics within 10 days or imipramine-class antidepressants within 21 days before SPT.
- Treatment with dupilumab or similar agents within 3 months before SPT.
- Treatment with omalizumab or similar agents within 5 months before SPT.
- Photochemotherapy on the volar surfaces of both forearms within 30 days before SPT.
- Skin infection, dermatitis, trauma, scarring, pigmentation, or other pathological changes at the intended volar forearm test site that, in the investigator's judgment, may interfere with SPT interpretation.
- Positive skin scratch test for dermographism during screening.
- Participation in another drug clinical trial with administration of an investigational product within 1 month before screening, or less than five elimination half-lives since the last administration of that investigational product, whichever period is longer.
- Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Skin Prick Test Group
All enrolled participants receive ragweed pollen SPT solution (3,500 DU/mL), dog dander SPT solution (19,500 DU/mL), dog dander SPT solution (39,000 DU/mL), and positive and negative control solutions during the same test session. |
One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later. One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later. One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later. |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Sensitivity: Ragweed Pollen (3,500 DU/mL)
Délai: 15-20 minutes after skin prick testing (Day 1).
|
Percentage of participants with a positive SPT result among participants with serum ragweed sIgE ≥0.70 kUA/L by ImmunoCAP (w1). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met. |
15-20 minutes after skin prick testing (Day 1).
|
|
Specificity: Ragweed Pollen (3,500 DU/mL)
Délai: 15-20 minutes after skin prick testing (Day 1).
|
Percentage of participants with a negative SPT result among participants with serum ragweed sIgE <0.70 kUA/L by ImmunoCAP (w1). An SPT is negative when maximum wheal diameter is <3 mm, provided control validity criteria are met. |
15-20 minutes after skin prick testing (Day 1).
|
|
Sensitivity: Dog Dander (19,500 DU/mL)
Délai: 15-20 minutes after skin prick testing (Day 1).
|
Percentage of participants with a positive SPT result among participants with serum dog dander sIgE ≥0.70 kUA/L by ImmunoCAP (e5). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met. |
15-20 minutes after skin prick testing (Day 1).
|
|
Specificity: Dog Dander (19,500 DU/mL)
Délai: 15-20 minutes after skin prick testing (Day 1).
|
Measure Description: Percentage of participants with a negative SPT result among participants with serum dog dander sIgE <0.70 kUA/L by ImmunoCAP (e5). An SPT is negative when maximum wheal diameter is <3 mm, provided control validity criteria are met. |
15-20 minutes after skin prick testing (Day 1).
|
|
Sensitivity: Dog Dander (39,000 DU/mL)
Délai: 15-20 minutes after skin prick testing (Day 1).
|
Percentage of participants with a positive SPT result among participants with serum dog dander sIgE ≥0.70 kUA/L by ImmunoCAP (e5). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met. |
15-20 minutes after skin prick testing (Day 1).
|
|
Specificity: Dog Dander (39,000 DU/mL)
Délai: 15-20 minutes after skin prick testing (Day 1).
|
Percentage of participants with a negative SPT result among participants with serum dog dander sIgE <0.70 kUA/L by ImmunoCAP (e5). An SPT is negative when maximum wheal diameter is <3 mm, provided control validity criteria are met. |
15-20 minutes after skin prick testing (Day 1).
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Adverse Events
Délai: From first skin prick administration (Day 1) through the final study visit (approximately 24 hours +4 hours after testing), with follow-up of unresolved events as required by protocol.
|
Number and percentage of participants experiencing adverse events, adverse drug reactions, serious adverse events, serious adverse drug reactions, and adverse events leading to withdrawal, by test solution as applicable. |
From first skin prick administration (Day 1) through the final study visit (approximately 24 hours +4 hours after testing), with follow-up of unresolved events as required by protocol.
|
|
Changes in Vital Signs from Baseline
Délai: At screening, within 2 hours before SPT, 1 hour ±10 minutes after SPT, and 24 hours ±4 hours after SPT.
|
Changes in vital signs from baseline will be assessed, including body temperature (°C), systolic and diastolic blood pressure (mmHg), and pulse rate (beats/min). Descriptive statistics, including mean, median, standard deviation, quartiles, minimum, and maximum, will be presented.Changes in vital signs will be summarized using cross-tabulations. Clinically significant abnormalities will be listed. |
At screening, within 2 hours before SPT, 1 hour ±10 minutes after SPT, and 24 hours ±4 hours after SPT.
|
|
Changes in Physical Examination Findings from Baseline
Délai: At screening and on Day 2 of the study or at early termination.
|
Changes in physical examination findings from baseline will be assessed, including skin and mucosa, lymph nodes, head and neck, chest, abdomen, and spine and extremities. Changes in examination findings will be summarized using cross-tabulations. Clinically significant abnormalities will be listed. |
At screening and on Day 2 of the study or at early termination.
|
|
Changes in Hematology Parameters from Baseline
Délai: At screening and on Day 2 of the study or at early termination.
|
Changes in hematology parameters from baseline will be assessed, including white blood cell count; absolute and percentage counts of neutrophils, lymphocytes, monocytes, eosinophils, and basophils; red blood cell count; hemoglobin; and platelet count. Units of measurement will follow the laboratory reports. Quantitative results will be summarized using the mean, median, standard deviation, quartiles, minimum, and maximum. Changes in clinical assessment categories will be summarized using cross-tabulations. Clinically significant abnormalities will be listed. |
At screening and on Day 2 of the study or at early termination.
|
|
Changes in Urinalysis Parameters from Baseline
Délai: At screening and on Day 2 of the study or at early termination.
|
Changes in urinalysis parameters from baseline will be assessed, including urine bilirubin, glucose, ketones, protein, occult blood, and leukocytes or leukocyte esterase. Results will be summarized according to the categories reported by the laboratory. Changes in results will be summarized using cross-tabulations. Clinically significant abnormalities will be listed. |
At screening and on Day 2 of the study or at early termination.
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- WOLWO-D1-0III32-1
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .